BDTX Valuation

Black Diamond Therapeutics Inc

Add to Watchlist

Advanced Chart

3.950

+0.08(2.067%)1D

BDTX Relative Valuation

BDTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BDTX is overvalued; if below, it's undervalued.

Historical Valuation

Black Diamond Therapeutics Inc (BDTX) is now in the Fair zone, suggesting that its current forward PS ratio of 3.87 is considered Fairly compared with the five-year average of -3.51. The fair price of Black Diamond Therapeutics Inc (BDTX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.87

Fair

-4.83

Trailing

Forward

-1.79

EV/EBITDA

Black Diamond Therapeutics Inc. (BDTX) has a current EV/EBITDA of -1.79. The 5-year average EV/EBITDA is -0.76. The thresholds are as follows: Strongly Undervalued below -5.25, Undervalued between -5.25 and -3.01, Fairly Valued between 1.48 and -3.01, Overvalued between 1.48 and 3.73, and Strongly Overvalued above 3.73. The current Forward EV/EBITDA of -1.79 falls within the Historic Trend Line -Fairly Valued range.

-1.68

EV/EBIT

Black Diamond Therapeutics Inc. (BDTX) has a current EV/EBIT of -1.68. The 5-year average EV/EBIT is -1.07. The thresholds are as follows: Strongly Undervalued below -5.18, Undervalued between -5.18 and -3.13, Fairly Valued between 0.99 and -3.13, Overvalued between 0.99 and 3.04, and Strongly Overvalued above 3.04. The current Forward EV/EBIT of -1.68 falls within the Historic Trend Line -Fairly Valued range.

3.95

Black Diamond Therapeutics Inc. (BDTX) has a current PS of 3.95. The 5-year average PS is 0.11. The thresholds are as follows: Strongly Undervalued below -1.14, Undervalued between -1.14 and -0.52, Fairly Valued between 0.73 and -0.52, Overvalued between 0.73 and 1.36, and Strongly Overvalued above 1.36. The current Forward PS of 3.95 falls within the Strongly Overvalued range.

-4.77

P/OCF

Black Diamond Therapeutics Inc. (BDTX) has a current P/OCF of -4.77. The 5-year average P/OCF is -3.08. The thresholds are as follows: Strongly Undervalued below -9.25, Undervalued between -9.25 and -6.17, Fairly Valued between 0.00 and -6.17, Overvalued between 0.00 and 3.09, and Strongly Overvalued above 3.09. The current Forward P/OCF of -4.77 falls within the Historic Trend Line -Fairly Valued range.

-4.61

P/FCF

Black Diamond Therapeutics Inc. (BDTX) has a current P/FCF of -4.61. The 5-year average P/FCF is -2.91. The thresholds are as follows: Strongly Undervalued below -8.27, Undervalued between -8.27 and -5.59, Fairly Valued between -0.23 and -5.59, Overvalued between -0.23 and 2.46, and Strongly Overvalued above 2.46. The current Forward P/FCF of -4.61 falls within the Historic Trend Line -Fairly Valued range.

Black Diamond Therapeutics Inc (BDTX) has a current Price-to-Book (P/B) ratio of 1.66. Compared to its 3-year average P/B ratio of 1.44 , the current P/B ratio is approximately 15.03% higher. Relative to its 5-year average P/B ratio of 1.50, the current P/B ratio is about 10.67% higher. Black Diamond Therapeutics Inc (BDTX) has a Forward Free Cash Flow (FCF) yield of approximately 8.11%. Compared to its 3-year average FCF yield of -48.72%, the current FCF yield is approximately -116.65% lower. Relative to its 5-year average FCF yield of -51.30% , the current FCF yield is about -115.81% lower.

1.69

P/B

Median3y

1.44

Median5y

1.50

0.08

FCF Yield

Median3y

-48.72

Median5y

-51.30

Competitors Valuation Multiple

The average P/S ratio for BDTX's competitors is 4.02, providing a benchmark for relative valuation. Black Diamond Therapeutics Inc Corp (BDTX) exhibits a P/S ratio of 3.95, which is -1.84% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BDTX.O

Black Diamond Therapeutics Inc

Caribou Biosciences Inc

Heron Therapeutics Inc

Cartesian Therapeutics Inc

Foghorn Therapeutics Inc

4.41

9.71%

237.99M

Performance Decomposition

Market capitalization of BDTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of BDTX in the past 1 year is driven by Unknown.